Sphera Funds Management’s Elevation Oncology ELEV Stock Holding History

Sphera Funds Management’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-328,562	Closed	-$121K	–	122
2025 Q2	$121K	Sell	328,562 -30,000	-8%	-$10K	0.03%	107
2025 Q1	$92.9K	Sell	358,562 -660,000	-65%	-$377K	0.02%	112
2024 Q4	$573K	Sell	1,018,562 -61,200	-6%	-$36.1K	0.1%	101
2024 Q3	$648K	Buy	1,079,762 +749,762	+227%	+$1.11M	0.1%	104
2024 Q2	$891K	Sell	330,000 -100,000	-23%	-$377K	0.12%	106
2024 Q1	$2.21M	Sell	430,000 -470,000	-52%	-$1.52M	0.31%	73
2023 Q4	$483K	Hold	900,000	–	–	0.08%	91
2023 Q3	$596K	Hold	900,000	–	–	0.11%	79
2023 Q2	$1.37M	Buy	+900,000	New	+$2.37M	0.21%	79
2021 Q3	–	Sell	-30,000	Closed	-$407K	–	126
2021 Q2	$407K	Buy	+30,000	New	+$371K	0.03%	129

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Sphera Funds Management's ELEV Position: Q3 2025 in Review

Sphera Funds Management sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 328,562 shares — an estimated $121K sold.

Sphera Funds Management first reported a position in ELEV in Q2 2021 and held it in 10 quarters. The position peaked at $2.21M in Q1 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Sphera Funds Management reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Sphera Funds Management sold 328,562 Elevation Oncology shares in Q3 2025, an estimated $121K.
Sphera Funds Management first reported a position in Elevation Oncology in Q2 2021 and held it in 10 quarters.
Sphera Funds Management's Elevation Oncology position peaked at $2.21M in Q1 2024.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Sphera Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.